







an Open Access Journal by MDPI

Chronic Viral Infections and Cancer, Openings for Therapies and Vaccines

Guest Editors:

Dr. Maria G. Isaguliants

- 1. Department of Research, Riga Stradins University, LV-1007 Riga, Latvia
- 2. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Dr. Alexander Ivanov

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Dr. Franco M. Buonaguro

Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy

Message from the Guest Editors

In this Special Issue, we aim to unravel the progress in the studies of the molecular pathogenesis of chronic viral infections and cover the common mechanisms of action of human oncogenic viruses, such as the activity of viral oncoproteins, the induction of genomic instability, the support of chronic inflammation, and the modulation of tumor microenvironment. Special attention will be devoted to virus-induced alterations in the functions of the immune system, to induction of innate and adaptive immune responses, including the relationship between immune and viral infections, metabolism. response immunometabolism, as well as to oncolytic viruses. Indepth understanding of these processes would create new openings for the design of novel viral vaccines and immunotherapies.

Deadline for manuscript submissions:

closed (31 January 2023)













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us